Edit |   |
---|---|
Antigenic Specificity | MAP2, Human |
Clone | REAL882 |
Host Species | Recombinant Human |
Reactive Species | human, mouse |
Isotype | n/a |
Format | fluorescein (FITC) conjugate |
Size | 200 µL |
Concentration | n/a |
Applications | MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | MAP2 Antibody, anti-human, FITC, REAdye_lease™. Clone REAL882 is an antibody fragment derived from the full MAP2 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity. | Clone REAL882 recognizes human MAP2, the Microtubule-associated protein 2, which is a memebr of the microtubule-associated protein family. MAP2 is found in brain and is mainly expressed in neurons. It has been reported, that it is also detected in different cancers including melanoma and breast cancer. Four isoforms of MAP2 have been characterized, MAP2A; MAP2B; MAP2C and MAP2D. MAP2D is expressed by glia cells. The MAP2 isoforms are thought to be involved in microtubule assembly. REAL882 does not recognize other MAPs or tubulin. | For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675). |
Immunogen | n/a |
Other Names | Microtubule-associated protein 2, MAP-2 |
Gene, Accession # | n/a |
Catalog # | 130-127-116 |
Price | $424 |
Order / More Info | MAP2, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Dehmelt, L. et al. (2005) The MAP2/Tau family of microtubule-associated proteins. Genome Biol. 6 (1): 204-204. | Soltani, M. H. et al. (2005) Microtubule-associated protein 2, a marker of neuronal differentiation, induces mitotic defects, inhibits growth of melanoma cells, and predicts metastatic potential of cutaneous melanoma. Am. J. Pathol. 166 (6): 1841-1850. | Wefer, A. K. et al. (2020) Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. Acta Neuropathologica 139 (1): 193-209. |